NBP
NovaBridge Biosciences
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Strong sell
-56/100
Last price
1.40
▲ 0.04 (2.94%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.37
Prev close
1.36
Day high
1.44
Day low
1.38
Volume
379.83K
Market cap
$162.40M
P/E (TTM)
—
52W range
1.31 – 6.79
Day trading desk
Gap from prior close
+0.74%
Prior close 1.36
VWAP
1.41
-0.38% from price
Relative volume
1.81×
Unusually busy
Session range
5.11%
1.37 – 1.44
Position in range
43%
Mid range
ATR (14D)
0.07
4.85% of price
Prior day high
1.38
PDH
Prior day low
1.35
PDL
Bid / ask spread
—
Quote not published
Session volume
734.11K
Avg 405.00K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.19%
+0.2%
1M
-22.22%
-23.4%
3M
-27.46%
-32.0%
6M
-43.55%
-61.7%
YTD
-64.82%
-79.1%
1Y
-67.59%
-84.0%
3Y
+6.06%
-76.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NBP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+507.83K
Net buying
Buy transactions
8
665.18K shares
Sell transactions
7
157.34K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
16.56M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | DENNIS PHILIP ANDREW Officer |
SELL | 8.21K | $13.13K | Direct |
| Sep 17, 26 | DENNIS PHILIP ANDREW Officer |
— | 23.70K | — | Direct |
| Sep 9, 26 | WUXIONG CAO SEAN Officer |
SELL | 107.98K | $183.56K | Direct |
| Sep 3, 26 | WUXIONG CAO SEAN Officer |
— | 339.37K | — | Direct |
| Aug 31, 26 | XU CONG CLAIRE Officer |
SELL | 3.28K | $5.97K | Direct |
| Aug 28, 26 | XU CONG CLAIRE Officer |
— | 9.38K | — | Direct |
| Aug 21, 26 | LENZ ROBERT A Director |
— | 17.22K | — | Direct |
| Jul 6, 26 | XU CONG CLAIRE Officer |
SELL | 4.49K | $9.02K | Direct |
| Jul 2, 26 | XU CONG CLAIRE Officer |
— | 12.43K | — | Direct |
| Jun 18, 26 | DENNIS PHILIP ANDREW Officer |
SELL | 8.49K | $12.74K | Direct |
| Jun 17, 26 | DENNIS PHILIP ANDREW Officer |
— | 23.70K | — | Direct |
| Jun 1, 26 | XU CONG CLAIRE Officer |
SELL | 3.49K | $5.97K | Direct |
| May 29, 26 | XU CONG CLAIRE Officer |
— | 9.38K | — | Direct |
| May 14, 26 | WUXIONG CAO SEAN Officer and Director |
SELL | 21.40K | $42.58K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DENNIS PHILIP ANDREW |
Officer | 173.43K | Sale |
HAGLER MARK ARNOLD |
President | 230.00K | Purchase |
LENZ ROBERT A |
Director | 17.22K | Conversion of Exercise of derivative security |
WUXIONG CAO SEAN |
Officer | 266.47K | Sale |
XU CONG CLAIRE |
Officer | 304.20K | Sale |
Fundamentals
Market cap$162.40M
Enterprise value$-23.99M
Revenue (TTM)—
Gross profit—
EBITDA$-122.53M
Net income$-117.55M
EPS (TTM)$-0.69
Free cash flow$-47.59M
Total cash$190.85M
Total debt$4.46M
Book value / share$1.73
Shares outstanding116.00M
Float64.45M
Short % of float7.16%
Dividend yield0.00%
Beta (5Y)1.60
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.32
PEG ratio—
Price / sales—
Price / book0.81
EV / revenue—
EV / EBITDA0.20
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-59.10%
Return on assets-34.98%
Debt / equity2.22
Current ratio7.64
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $632.00K | -$1.55M | — | — |
| Operating revenue | $0 | $0 | $632.00K | -$1.55M | — | — |
| Cost of revenue | — | — | $0 | $3.95M | $7.28M | — |
| Gross profit | — | — | $3.90M | -$36.06M | $6.53M | — |
| Research & development | $62.91M | $21.77M | $21.45M | $22.55M | — | +189.0% |
| Selling, general & admin | $31.36M | $29.66M | $28.16M | $28.98M | — | +5.8% |
| Total operating expense | $94.27M | $51.43M | $49.61M | $51.53M | — | +83.3% |
| Operating income | -$94.27M | -$51.43M | -$48.98M | -$53.08M | — | -83.3% |
| Net interest income | $7.61M | $7.49M | $9.29M | $4.95M | — | +1.7% |
| Pre-tax income | -$88.34M | -$49.70M | -$82.22M | -$141.10M | — | -77.8% |
| Tax provision | $0 | $0 | $0 | $103.00K | — | — |
| Net income | -$46.27M | -$22.23M | -$207.73M | -$371.05M | — | -108.1% |
| Net income to common | -$46.27M | -$22.23M | -$207.73M | -$371.05M | — | -108.1% |
| Basic EPS | -0.48 | -0.28 | -2.33 | -4.24 | — | -75.0% |
| Diluted EPS | -0.48 | -0.28 | -2.33 | -4.24 | — | -75.0% |
| EBIT | -$94.27M | -$51.43M | -$48.98M | -$53.08M | — | -83.3% |
| EBITDA | -$93.41M | -$50.45M | -$47.91M | -$51.66M | — | -85.2% |
| Basic shares | 95.76M | 81.19M | 88.65M | 82.52M | — | +18.0% |
| Diluted shares | 95.76M | 81.19M | 88.65M | 82.52M | — | +18.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $210.63M | $68.26M | $291.51M | $465.85M | — | +208.6% |
| Cash & short-term investments | $210.84M | $173.40M | $311.73M | $499.97M | — | +21.6% |
| Accounts receivable | — | — | — | $0 | $5.19M | — |
| Inventory | — | — | — | $0 | $4.27M | — |
| Total current assets | $217.52M | $176.69M | $329.91M | $525.63M | — | +23.1% |
| Property, plant & equipment | $2.95M | $3.80M | $5.55M | $17.97M | — | -22.4% |
| Goodwill & intangibles | — | — | $16.66M | $40.80M | $44.28M | — |
| Total assets | $260.52M | $212.68M | $368.92M | $590.45M | — | +22.5% |
| Total current liabilities | $26.89M | $8.45M | $58.14M | $109.89M | — | +218.1% |
| Current debt | — | — | $4.23M | $2.75M | — | — |
| Long-term debt | — | — | $8.31M | — | — | — |
| Total debt | $3.07M | $3.88M | $3.89M | $10.87M | — | -21.0% |
| Total liabilities | $29.58M | $11.52M | $126.34M | $168.68M | — | +156.8% |
| Retained earnings | -$1.33B | -$1.29B | -$1.26B | -$994.62M | — | -3.6% |
| Shareholder equity | $230.94M | $201.16M | $242.58M | $421.77M | — | +14.8% |
| Working capital | $190.63M | $168.24M | $271.77M | $415.74M | — | +13.3% |
| Net tangible assets | $230.94M | $201.16M | $242.58M | $380.97M | — | +14.8% |
| Shares issued | 270.74M | 196.33M | 194.07M | 190.88M | — | +37.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$88.34M | -$49.70M | -$82.22M | -$141.20M | -77.8% |
| Depreciation & amortisation | $856.00K | $978.00K | $1.06M | $1.42M | -12.5% |
| Stock-based compensation | $5.97M | -$1.95M | $10.24M | $13.15M | +406.5% |
| Change in working capital | $17.07M | -$2.81M | -$37.12M | $17.09M | +707.4% |
| Operating cash flow | -$20.60M | -$52.67M | -$72.70M | -$49.58M | +60.9% |
| Capital expenditure | -$7.00K | -$48.00K | -$164.00K | -$2.09M | +85.4% |
| Investing cash flow | $104.97M | -$136.01M | -$15.16M | -$5.18M | +177.2% |
| Share buybacks | $0 | -$335.00K | -$8.64M | -$3.01M | +100.0% |
| Financing cash flow | $57.73M | -$335.00K | -$8.24M | $3.91M | +17,331.3% |
| Free cash flow | -$20.60M | -$52.72M | -$72.86M | -$51.67M | +60.9% |
| End cash position | $210.63M | $68.26M | $310.67M | $475.37M | +208.6% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $55.66M | $3.18M | $3.29M | $777.00K | +1,652.5% |
| Selling, general & admin | $17.24M | $5.81M | $3.82M | $4.49M | +196.6% |
| Total operating expense | $72.90M | $8.99M | $7.11M | $5.27M | +711.0% |
| Operating income | -$72.90M | -$8.99M | -$7.11M | -$5.27M | -711.0% |
| Net interest income | $1.79M | $2.15M | $1.80M | $1.87M | -16.5% |
| Pre-tax income | -$72.86M | -$6.83M | -$5.50M | -$3.15M | -967.0% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$30.79M | -$6.83M | -$5.50M | -$3.15M | -350.9% |
| Net income to common | -$30.79M | -$6.83M | -$5.50M | -$3.15M | -350.9% |
| Basic EPS | — | — | -0.07 | -0.05 | — |
| Diluted EPS | — | — | -0.07 | -0.05 | — |
| EBIT | -$72.90M | -$8.99M | -$7.11M | -$5.27M | -711.0% |
| EBITDA | -$72.68M | -$8.77M | -$7.11M | -$5.27M | -728.5% |
| Basic shares | — | — | 81.70M | 81.60M | — |
| Diluted shares | — | — | 81.70M | 81.60M | — |
| Line item | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $190.64M | $210.63M | $228.06M | $165.40M | $53.60M | -9.5% |
| Cash & short-term investments | $190.85M | $210.84M | $228.27M | $165.61M | $168.62M | -9.5% |
| Total current assets | $198.00M | $217.52M | $232.78M | $167.64M | $173.23M | -9.0% |
| Property, plant & equipment | $5.61M | $2.95M | $3.17M | $3.38M | $3.59M | +90.2% |
| Total assets | $231.54M | $260.52M | $277.41M | $206.71M | $208.94M | -11.1% |
| Total current liabilities | $25.92M | $26.89M | $16.09M | $7.35M | $7.75M | -3.6% |
| Total debt | $4.46M | $3.07M | $3.27M | $3.48M | $3.68M | +45.4% |
| Total liabilities | $30.44M | $29.58M | $18.50M | $9.97M | $10.60M | +2.9% |
| Retained earnings | -$1.37B | -$1.33B | -$1.30B | -$1.29B | -$1.29B | -2.8% |
| Shareholder equity | $201.10M | $230.94M | $258.92M | $196.73M | $198.34M | -12.9% |
| Working capital | $172.08M | $190.63M | $216.68M | $160.29M | $165.48M | -9.7% |
| Net tangible assets | $201.10M | $230.94M | $258.92M | $196.73M | $198.34M | -12.9% |
| Shares issued | 265.38M | 270.74M | 270.74M | 196.98M | 196.69M | -2.0% |
| Line item | 2025-12-31 | 2025-09-30 | YoY |
|---|---|---|---|
| Net income | -$72.86M | -$6.83M | -967.0% |
| Depreciation & amortisation | $216.00K | $216.00K | 0.0% |
| Stock-based compensation | $3.94M | $1.46M | +170.8% |
| Change in working capital | $10.28M | $6.99M | +47.0% |
| Operating cash flow | -$14.60M | $1.84M | -893.7% |
| Investing cash flow | $0 | $0 | — |
| Share buybacks | $0 | $0 | — |
| Financing cash flow | -$3.02M | $60.75M | -105.0% |
| Free cash flow | -$14.60M | $1.84M | -893.7% |
| End cash position | $210.63M | $228.06M | -7.6% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+78.6% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
3
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -0.08 | -0.31 | -287.5% |
| Sep 2025 | -0.05 | -0.06 | -20.0% |
| Jun 2025 | -0.12 | -0.07 | +41.7% |
| Mar 2025 | -0.07 | -0.04 | +38.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | 0.0% |
| Next quarter | — | — | $0 | 0.0% |
| Current year | -0.91 | 1 | $0 | 0.0% |
| Next year | -0.63 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$9.00
High target$9.00
Low target$9.00
Implied upside542.86%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders14.28%
Held by institutions34.23%
Institutions holding62
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.39
+0.65% from price
SMA 20
1.50
-6.95% from price
SMA 50
1.68
-16.89% from price
SMA 100
1.72
-18.57% from price
SMA 200
2.43
-42.44% from price
EMA 12
1.43
-2.06% from price
EMA 26
1.54
-8.84% from price
EMA 50
1.64
-14.73% from price
RSI (14)
34.1
Neutral
MACD (12,26,9)
-0.11
Hist -0.01
ATR (14)
0.07
4.85% of price
Realised vol 30D
41.0%
Annualised
Bollinger upper
1.75
20, 2σ
Bollinger lower
1.26
20, 2σ
50 / 200 cross
Death
1.68 vs 2.43
Trend bias
Below 200
-42.44%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.55
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
41.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-79.6%
Peak to trough
Max drawdown 5Y
-99.2%
Peak to trough
ATR 14
0.07
4.85% of price
Beta (reported)
1.60
5Y monthly, from filing
Short interest
Shares short
3.75M
Prior 4.58M
Change vs prior
-18.1%
Shorts covering
% of float
7.16%
Normal
% of shares out
3.23%
Against total outstanding
Days to cover
14.4
Crowded exit
Float
64.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 24, 25 | BTIG | MAINTAINED | Buy | Buy |
| Oct 17, 25 | BTIG | MAINTAINED | Buy | Buy |
| Oct 3, 25 | Leerink Partners | INITIATED | — | Outperform |
| Sep 10, 25 | BTIG | MAINTAINED | Buy | Buy |
| Sep 9, 25 | BTIG | INITIATED | — | Buy |
| Sep 8, 25 | Needham | MAINTAINED | Buy | Buy |
| Aug 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-08
Corporate Changes & Voting Matters
6-K · 2026-08-20
Offering Registrations
S-8 · 2026-08-17
Corporate Changes & Voting Matters
6-K · 2026-07-24
Corporate Changes & Voting Matters
6-K · 2026-07-17
Corporate Changes & Voting Matters
6-K · 2026-06-29
Periodic Financial Reports
20-F/A · 2026-06-16
Corporate Changes & Voting Matters
6-K · 2026-04-22
Headlines
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
GlobeNewswire · 29d ago
NovaBridge Biosciences to Participate in September Investor Conferences
GlobeNewswire · 41d ago
NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ...
GuruFocus.com · 47d ago
NovaBridge Biosciences Q2 2026 Earnings Call Summary
Moby · 48d ago
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
GlobeNewswire · 48d ago
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
GlobeNewswire · 54d ago
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
GlobeNewswire · 74d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.